MOVING ON2 Feb 2022 15:18
"The achievement of this important milestone in the VERSATILE-002 Phase 2 clinical trial strengthens the evidence of our novel Versamune® platform's potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression," commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. "The initial data solidifies our belief that PDS0101's demonstrated preclinical efficacy when combined with KEYTRUDA® has the potential to significantly improve clinical outcomes for patients with advanced HPV16-positive head and neck cancers."